AbbVie's Rinvoq continues march with NICE nod in rheumatoid arthritis

abbvie
AbbVie's Rinvoq has nabbed just $14 million in sales since its approval in August with fourth-quarter earnings due next week, but its reimbursement reach is rapidly growing. (AbbVIe)

With its Allergan merger likely in the final stages, AbbVie is placing its hopes in a pair of home-grown drugs to help weather biosimilar attacks against Humira. One of those, JAK inhibitor Rinvoq, just snagged a big win from England's cost watchdog. 

The National Institute for Health and Care Excellence has recommended AbbVie's Rinvoq, added to standard-of-care methotrexate, for coverage on the National Health Service as a treatment for severe rheumatoid arthritis, according to draft guidance published Friday. 

Rinvoq, with a list price of £805.56 ($1,058.06) per 28-day pack and average annual cost per patient of £10,508 ($13,801), will come with a confidential discount, NICE said. 

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

Despite the win in severe RA, though, NICE knocked down Rinvoq's application to treat moderate RA, arguing the drug's price didn't hit its cost-effectiveness standard in that indication. 

RELATED: Pro-AbbVie bias may be driving rheumatologist confidence in newcomer Rinvoq: analyst

Suggested Articles

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.

Alexion and Amgen reached a deal to put off a biosimilar challenger to Alexion's blockbuster rare disease med Soliris until March 2025.